Navigation Links
Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
Date:9/15/2008

Journalists are invited to attend the 20th EORTCNCIAACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland [Geneva Palexpo, Geneva] from Tuesday 21 October-Friday 24 October.

Today (Monday 15 September) is the deadline for booking accommodation via the official local agent if you wish to attend this symposium, organised jointly by the European Organisation for the Research and Treatment of Cancer, the US National Cancer Institute and the American Association for Cancer Research.

The symposium offers:

  • Cutting edge information on new cancer drug research and development from experts in Europe, North America, Asia and Australia;
  • Free registration for bona fide media with official press credentials (press card and/or a commissioning letter from the editor of the journal/website they represent);
  • All sessions open to journalists;
  • Media centre with free computing, fax, international phone, internet and photocopying facilities;
  • Two news briefings (12.15 hrs CEST: Wednesday 22 October and Thursday 23 October)

Topics at the news briefings or to be press released include:

  • Crossing the blood-brain barrier: scientists develop a new drug delivery system for hard-to-treat cancers of the central nervous system;
  • New "spindle poisoning" drug shows promise in phase I trial of solid tumours: phase II trials planned;
  • Scientists discover pattern of gene expression that predicts response to treatment in advanced colorectal cancer;
  • New drug shows impressive activity in patients with advanced disease, including medullary thyroid cancer. Phase III trials planned;
  • Researchers discover that a genetic mutation makes metastatic colorectal cancer patients resistant to anti-EGFR drugs. Potential for a biomarker to select patients who would respond to treatment;
  • Cancer vaccine shows promise in patients with bowel, kidney and prostate cancer: phase III trials on-going.

Please note: the details contained in this media alert are for information only and are embargoed until the time of the news briefings or press releases.

The symposium is an opportunity for journalists to listen and talk to some of the 2,200 European, American and other international experts in oncology gathered in Geneva to share findings on the latest research on new molecular targets, designer diagnostics and prognostics, smart drugs and other novel approaches to cancer treatment.

NB: the official language of the symposium is English and all press materials will be in English.

Journalists should register to attend the symposium by downloading a registration form at: http://www.ecco-org.eu/ or by contacting Riitta Kettunen:
Email: Riitta.Kettunen@ecco-org.eu
Tel: +32 2 775 02 05
Fax: +32 2 775 02 00

More information on the programme and hotel accommodation is available on the EORTC-NCI-AACR symposium website at: http://www.ecco-org.eu/

Accommodation

This should be booked through Symporg SA, the official local agent for the symposium, via the symposium website. Symporg, SA
Tel: +41-22 839 84 84
Fax: +41-22 839 84 85
Email: info@symporg.ch

NB: the deadline for hotel reservations is September 15. Reservations are made on a first-come, first served basis and you are advised to book early.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-077-112-96986
ECCO-the European CanCer Organisation
Source:Eurekalert

Related biology news :

1. September Geology and GSA Today media highlights
2. Heart of Herschel to be presented to media
3. Last chance for media to register for ECCO 14 -- the European Cancer Conference
4. October Geology and GSA Today media highlights
5. Media highlights in the November issues of Biophysical Journal
6. November GEOLOGY and GSA TODAY Media Highlights
7. Nanotechnology and the media: The inside story
8. December GEOLOGY and GSA TODAY media highlights
9. Better protection for biomedial devices could result from Rutgers-Camden research
10. Media highlights in the Dec. 15 issue of Biophysical Journal
11. Immediate action needed to save corals from climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: